Samsung Bioepis announced on the 5th that it has signed a joint research agreement with IntuCell to validate development candidates in the antibody-drug conjugate (ADC) field.
Under this agreement, IntuCell will provide proprietary linker and drug (Payload·Toxin·Drug) technologies. Samsung Bioepis will manufacture ADC substances targeting up to five anticancer targets and evaluate their characteristics.
Samsung Bioepis will verify IntuCell's ADC technology competitiveness, including animal testing. The two companies agreed to discuss whether to exercise development options and other details based on the validation results. The research contract period and total contract scale are confidential.
Jo Ho-sung, Head of Advanced Development Division (Vice President) at Samsung Bioepis, said, "We look forward to collaborating with IntuCell, which has excellent technology in the core ADC fields of linker and drug," adding, "Based on the development capabilities accumulated through the biosimilar business, this contract was signed as part of exploring various new business opportunities to address unmet patient needs."
Park Tae-gyo, CEO of IntuCell, stated, "We believe that Samsung Bioepis's extensive experience and speedy development capabilities combined with IntuCell's new linker-drug technology form the best combination to maximize synergy," and added, "IntuCell will do its best to achieve successful results for both companies."
Founded in 2015, IntuCell is a company focused on ADC linker-drug development, possessing technologies that stably connect and release various forms of drugs, technologies that increase ADC selectivity, and multiple Nexatecan-type drugs, a new camptothecin-class drug. In January, it also licensed technology to ADC Therapeutics, a company specializing in ADC development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
